Inventor · disambiguated record
Joerg Thomas Regula
Also filed as: REGULA JOERG · REGULA JOERG THOMAS
52 granted patents·62 pending applications·560 citations·filing 2005–2025
98Inventor score
Top patents by PatentIndex Score
114 records- 0197US11673945B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2020·Granted Jun 13, 2023·4 cites·9 claims
- 0297US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 0397US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 0497US9695233B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2013·Granted Jul 4, 2017·44 cites·11 claims
- 0597US9382323B2Multispecific antibodies comprising full length antibodies and single chain fab fragmentsBRINKMANN ULRICH·Filed 2010·Granted Jul 5, 2016·77 cites·22 claims
- 0697US8268314B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2009·Granted Sep 18, 2012·70 cites·18 claims
- 0796US10392445B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 27, 2019·31 cites·39 claims
- 0895US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0995US8703132B2Bispecific, tetravalent antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Apr 22, 2014·64 cites·11 claims
- 1095US8133979B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2009·Granted Mar 13, 2012·19 cites·10 claims
- 1194US11613576B2Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2020·Granted Mar 28, 2023·3 cites·29 claims
- 1294US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 1394US8703130B2Bispecific anti-VEGF/anti-ANG-2 antibodiesBAEHNER MONIKA·Filed 2012·Granted Apr 22, 2014·23 cites·12 claims
- 1492US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 1592US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 1692US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 1792US9708396B2Bispecific anti-VEGF/anti-ANG-2 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Jul 18, 2017·16 cites·17 claims
- 1892US8361747B2Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2012·Granted Jan 29, 2013·10 cites·4 claims
- 1991US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 2091US10683345B2Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseasesROCHE GLYCART AG·Filed 2017·Granted Jun 16, 2020·5 cites·16 claims
- 2191US10611825B2Monovalent antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted Apr 7, 2020·6 cites·8 claims
- 2291US9982036B2Dual FC antigen binding proteinsBOSSENMAIER BIRGIT·Filed 2012·Granted May 29, 2018·12 cites·3 claims
- 2391US8399626B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2012·Granted Mar 19, 2013·9 cites·5 claims
- 2490US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 2590US11958912B2Method for determining the in vivo interaction modeHOFFMANN LA ROCHE·Filed 2020·Granted Apr 16, 2024·2 cites·34 claims
- 2690US11091541B2Human FcRn-binding modified antibodies and methods of useHOFFMANN LA ROCHE·Filed 2015·Granted Aug 17, 2021·6 cites·7 claims
- 2790US10287352B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2016·Granted May 14, 2019·10 cites·21 claims
- 2890US7807158B2Antibodies against IL-13 receptor alpha1 and uses thereofROCHE PALO ALTO LLC·Filed 2006·Granted Oct 5, 2010·19 cites·9 claims
- 2989US11130810B2Bispecific antibodies specific for PD1 and TIM3HOFFMANN LA ROCHE·Filed 2019·Granted Sep 28, 2021·4 cites·36 claims
- 3089US7625996B2Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol)HOFFMANN LA ROCHE·Filed 2007·Granted Dec 1, 2009·14 cites·9 claims
- 3188US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 3287US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 3387US2025101135A1Antigen binding molecules comprising a tnf family ligand trimerHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 3487US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3585US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 3684US10640555B2Bispecific antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted May 5, 2020·2 cites·2 claims
- 3784US9340609B2Antibodies against human angiopoietin 2HOFFMANN LA ROCHE·Filed 2012·Granted May 17, 2016·3 cites·5 claims
- 3884US2023399391A1Bispecific anti-vegf/anti-ang-2 antibodiesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3984US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4083US12264196B2Fc-receptor binding modified asymmetric antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Granted Apr 1, 2025·1 cites·14 claims
- 4183US10730938B2Bispecific antibodies and methods of use in ophthalmologyHOFFMANN LA ROCHE·Filed 2017·Granted Aug 4, 2020·3 cites·13 claims
- 4283US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 4382US12227573B2Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2023·Granted Feb 18, 2025·0 cites·45 claims
- 4482US8552158B2Method for the production of insulin-like growth factor-1FISCHER STEPHAN·Filed 2007·Granted Oct 8, 2013·2 cites·4 claims
- 4582US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 4682US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 4781US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 4881US9676845B2Bispecific antigen binding proteinsIMHOF-JUNG SABINE·Filed 2010·Granted Jun 13, 2017·5 cites·8 claims
- 4981US9109027B2Antibodies against human angiopoietin 2BRINKMANN ULRICH·Filed 2012·Granted Aug 18, 2015·2 cites·2 claims
- 5080US12441812B2Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
Showing the top 50 of 114 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Joerg Thomas Regula files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →